Pulmatrix, Inc. (“Pulmatrix”) (Nasdaq: PULM), a clinical-stage biopharmaceutical company, announces a merger agreement with Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases. Cullgen utilizes its proprietary technology platform, uSMITE™, featuring novel E3 ligands, to build the next generation of targeted protein degraders and degrader-antibody conjugates (“DACs”).
Read the full article: Pulmatrix and Cullgen Announce Proposed Merger //
Source: https://www.prnewswire.com/news-releases/pulmatrix-and-cullgen-announce-proposed-merger-302303818.html